Abstract
Several hypotheses link altered microbial exposure in affluent societies to increased prevalence of allergies, but none have been experimentally tested in humans. Here we capitalize on the opportunity to study a cohort of infants (CORAL) raised during COVID-19 associated social distancing measures to test the interactions between bacterial exposure and fecal microbiome composition with atopic outcomes. We show that fecal Clostridia levels were significantly lower in CORAL infants and correlated with a microbial exposure index. Microbiota composition was the most significant component of regression models predicting risk of atopic dermatitis (AUC 0.86) or food allergen sensitization (AUC 0.98) and mediated the effects of multiple environment factors on disease risk. Although diet had a larger effect on microbiota composition than environmental factors linked to dispersal, most effects were mediated through the microbiota. This study provides critical information to refine existing hypothesis on the importance of the gut microbiota to immune development.
Competing Interest Statement
C. Venter reports grants from Reckitt Benckiser, Food Allergy Research and Education, and National Peanut Board, and personal fees from Reckitt Benckiser, Nestle Nutrition Institute, Danone, Abbott Nutrition, Else Nutrition, and Before Brands. L. O Mahony reports consultancy with Precision BioticsAlimentary Health, grants from GlaxoSmithKline and Chiesi, and participation in speaker bureau for Nestle, Yakult, Reckitt and Abbott. J. Hourihane is a board member of Clemens Von Pirquet Foundation. No other conflicts were declared for the remaining authors.
Funding Statement
This work was supported by Royal College of Surgeons in Ireland, Temple Street Hospital Foundation in Dublin, Ireland (Approval number RPAC 20-02), and the Clemens Von Pirquet Foundation in Geneva, Switzerland. The authors are supported by a Science Foundation Ireland research center grant 12/RC/2273_P2.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Research Ethics Committee for COVID-19-related Research (NREC COVID-19) of Ireland gave ethical approval for this work (Approval number 20-NREC-COV-067)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
